drugset / Trial / NCT05051579
A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities
RandomizedParallel-groupDouble-blindTreatment
Summary
The main purpose of the study was to assess the effect of LY3502970 in participants who have obesity or are overweight.
Timeline
- Start
- 2021-09-29
- Primary completion
- 2022-08-25
- Completion
- 2022-11-22
Outcome
Met primary endpoint
registry analysis (superiority test); 12 mg LY3502970 vs Placebo; p <0.001; LS Mean difference (Final Values) -6.5 (95% CI -8.9 to -4.2); Mixed Models Analysis NCT05051579 ↗
paper At week 26, the mean change from baseline in body weight ranged from -8.6% to -12.6% across the orforglipron dose cohorts and was -2.0% in the placebo group. PMID 37351564 ↗
Publications
- Wharton S, Rosenstock J, Konige M, Lin Y, Duffin K, Wilson J, Banerjee H, Pirro V, Kazda C, Mather K. Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes. Cardiovasc Diabetol. 2025 Jun 6;24(1):240. doi: 10.1186/s12933-025-02781-x.
- Wharton S, Blevins T, Connery L, Rosenstock J, Raha S, Liu R, Ma X, Mather KJ, Haupt A, Robins D, Pratt E, Kazda C, Konig M; GZGI Investigators. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. N Engl J Med. 2023 Sep 7;389(10):877-888. doi: 10.1056/NEJMoa2302392. Epub 2023 Jun 23.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Orforglipron | Small molecule | 12 mg | Oral |
| Subject | Orforglipron | Small molecule | 24 mg | Oral |
| Subject | Orforglipron | Small molecule | 36 mg | Oral |
| Subject | Orforglipron | Small molecule | 45 mg | Oral |